Clinical Study to Evaluate Different Energy-based Devices for Aesthetic Treatments.

Sponsor
Cynosure, Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT06111482
Collaborator
(none)
50
1
4
16.2
3.1

Study Details

Study Description

Brief Summary

The goal of the energy-based devices used in this study is to evaluate their safety and performance to treat unwanted dermatologic conditions.

Condition or Disease Intervention/Treatment Phase
  • Device: Intense pulsed light.
  • Device: Radiofrequency microneedling device
  • Device: Radiofrequency device
  • Device: Combined energy devices
N/A

Detailed Description

Up to 50 subjects will be enrolled at 1 study center. Subjects will be enrolled into 4 groups: Group A, Group B, Group C, or Group D. Subjects may enroll in more than one group, however the last treatment in the previous group would be at least 30 days before the subject is enroll in the next group if treatment area is the same.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
50 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Subjects will be treated with an intended pulsed light device. Subjects may also receive split treatments where one side of the face and/or body will be treated with the study device, and the contralateral side will be treated with a similar IPL device or a similar microneedling device. Randomization will not be used as the group the subject will be assigned to will be determined based on dermatologic condition the subject presents with and this will be determined by the Investigator.Subjects will be treated with an intended pulsed light device. Subjects may also receive split treatments where one side of the face and/or body will be treated with the study device, and the contralateral side will be treated with a similar IPL device or a similar microneedling device. Randomization will not be used as the group the subject will be assigned to will be determined based on dermatologic condition the subject presents with and this will be determined by the Investigator.
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Clinical Study to Evaluate Different Energy-based Devices for Aesthetic Treatments.
Actual Study Start Date :
Sep 28, 2023
Anticipated Primary Completion Date :
Feb 1, 2025
Anticipated Study Completion Date :
Feb 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Experimental: IPL only

Group A will be treated with an intense pulsed light (IPL) device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar IPL device that is cleared for use by the FDA.

Device: Intense pulsed light.
The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Experimental: RF Microneedling Only

Group B will be treated with a radiofrequency (RF) microneedling device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF microneedling device that is cleared for use by the FDA.

Device: Radiofrequency microneedling device
The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Experimental: RF Only

Group C will be treated with an RF device only. They may also receive split treatments where one side of the face and/or body will be treated with the study device and the contralateral side will be treated with a similar RF device that is cleared for use by the FDA.

Device: Radiofrequency device
The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Experimental: Combination

Group D will receive combination treatments and will be treated with 2 or more of the study devices.

Device: Intense pulsed light.
The intense pulsed light (IPL) will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Device: Radiofrequency microneedling device
The microneedling device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Device: Radiofrequency device
The radio frequency device will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Device: Combined energy devices
The combined energy devices will be used for treating unwanted dermatologic conditions which may be on multiple areas of the body such as, but not limited to, the face, décolletage, back, legs, arms, and hands.

Outcome Measures

Primary Outcome Measures

  1. Maximum pain reported during treatment. [procedure (during device treatment)]]

    The maximum pain during treatment per each device will be reported on a scale of 0(none) to 10 (maximum intolerable pain). This pain is recorded during when the patient is actively treated (when the patient comes in and receives a treatment from the device).

Eligibility Criteria

Criteria

Ages Eligible for Study:
22 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • A healthy male or female 22 years of age or older.

  • Willing to undergo at least 1 treatment with the study device(s).

  • Understands and accepts obligation not to receive any other procedures in the treatment area through the length of the study.

  • Understands and accepts the obligation and is logistically able to be present for all visits.

  • Is willing to comply with all requirements of the study and sign the informed consent document

Exclusion Criteria:
  • Is female and pregnant, has been pregnant within the last 3 months, is currently breast feeding or planning a pregnancy during the study period.

  • Takes or has taken oral isotretinoin, such as Accutane®, within the last six months.

  • Is using systemic steroids (e.g., prednisone, dexamethasone) prior to or during the course of treatment.

  • Is receiving or has received gold therapy.

  • Is taking medications that alter the wound-healing response or has a history of healing problems.

  • Has an active localized or systemic infection, or an open wound in area being treated.

  • Has a significant systemic illness, such as lupus, or an illness localized in area being treated.

  • Has a seizure disorders triggered by light.

  • Has a history of skin photosensitivity disorders.

  • Has a history of hypertrophic scars or keloid formation.

  • Has a history of radiation therapy in area to be treated.

  • Received fillers or neurotoxin injections in the treatment area within the past 2 weeks.

  • Has had a chemical or mechanical epilation within the last six weeks.

  • Currently enrolled in an investigational drug or device trial or has received an investigational drug or been treated with an investigational device within the area to be treated 6 months to entering this study.

  • Has any condition or is in a situation which in the investigator's opinion may put the subject at significant risk, may confound study results or may interfere significantly with the subject's participation.

Radiofrequency Device Only:
  • Has a Pacemaker

  • Has any embedded electronic devices that give or receive a signal.

  • Has electronic implants, such as Implantable Cardiac Defibrillators (ICD) or Cardiac Resynchronization Therapy (CRT) devices: treatment may interfere with the functionality of the device and/or damage the electronic implant.

  • Is allergic to adhesives such as glues on medical tape: they should be alerted that a rash may occur on the neutral electronic monitoring pad (NEM or neutral pad) site, and an over-the-counter preparation may be used to treat the area.

  • Has nerve insensitivity to heat in the treatment area or in the neutral pad placement area.

  • Is allergic to topical anesthetic

Contacts and Locations

Locations

Site City State Country Postal Code
1 Cynosure Westford Massachusetts United States 01886

Sponsors and Collaborators

  • Cynosure, Inc.

Investigators

  • Principal Investigator: Sean Doherty, Cynosure, LLC

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Cynosure, Inc.
ClinicalTrials.gov Identifier:
NCT06111482
Other Study ID Numbers:
  • EUN-PL01-2023
First Posted:
Nov 1, 2023
Last Update Posted:
Nov 1, 2023
Last Verified:
Oct 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
Yes
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 1, 2023